Bio Usawa Biotech

Bio Usawa is a biopharmaceutical company focused on increasing the accessibility and affordability of biologic medicines in Africa and other underserved markets. The company specializes in the development and local production of biosimilar monoclonal antibodies, with a primary focus on oncology and chronic inflammatory conditions. By leveraging technology transfer and establishing regional manufacturing capabilities, Bio Usawa seeks to address the high cost of imported biologics and improve patient outcomes across the continent. Their lead programs include biosimilar versions of essential therapies such as trastuzumab and rituximab. The organization emphasizes a sustainable business model that integrates R&D with local biomanufacturing to ensure a reliable supply chain for life-saving treatments.